Home » Topics » BioWorld Science

BioWorld Science
RSS

Daiichi Sankyo begins phase I study in Japan with DS-2741a for atopic dermatitis

Jan. 27, 2020

Phase III BREEZE-AD4 trial of baricitinib in atopic dermatitis meets primary endpoint

Jan. 27, 2020

Phase I results with EPX-100 pave way for phase II studies in Dravet syndrome

Jan. 27, 2020

Brilinta improves outcomes after acute ischemic stroke or TIA in phase III trial

Jan. 27, 2020

Dynacure studies DYN-101 in phase I/II trial for centronuclear myopathies

Jan. 27, 2020

CStone begins phase III study of CS-1003 in advanced hepatocellular carcinoma

Jan. 27, 2020

Pivotal DESTINY-Gastric01 trial of DS-8201 meets primary endpoint

Jan. 27, 2020

Phase III study of AKP-01 spray in mild to moderate plaque psoriasis meets primary endpoint

Jan. 27, 2020

PDE3A influences endothelial function and risk of ischemic stroke

Jan. 27, 2020

The University of Minnesota presents psi-glutathione compounds

Jan. 27, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...